Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) has provided an announcement.
Zymeworks said partner Jazz Pharmaceuticals will present four new data sets on Ziihera, or zanidatamab-hrii, at the 2026 AACR Annual Meeting in San Diego, underscoring the drug’s expanding clinical profile beyond its current indication in HER2-positive biliary tract cancer. The package includes Phase 2 NeoZanHER trial results in early-stage HER2-positive breast cancer showing significant tumor reductions and a 30% pathologic complete response rate at six weeks, alongside mechanistic and multi-omics analyses that highlight zanidatamab’s differentiated HER2 biology and potential activity after progression on trastuzumab deruxtecan, reinforcing its positioning as a versatile HER2-targeted therapy across multiple solid tumors.
Additional AACR presentations will explore zanidatamab in a tumor-agnostic Phase 2 study of previously treated HER2-overexpressing solid tumors and in an adaptive, biomarker-driven organ-preservation trial in gastroesophageal adenocarcinoma. Together, these studies may broaden the clinical and commercial opportunity for Ziihera and support Zymeworks’ strategy of leveraging partnerships and innovative trial designs to entrench the drug’s role in the competitive HER2 oncology landscape.
The most recent analyst rating on (ZYME) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Overall score reflects a strong earnings-call outlook (clinical validation, regulatory path, improved FY2025 performance, and nondilutive financing) offset by weak underlying financial performance (recent losses and ongoing cash burn) and neutral technicals; valuation remains challenged due to unprofitability (negative P/E).
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a biotechnology company that manages a portfolio of licensed healthcare assets while developing a pipeline of novel, multifunctional biotherapeutics. The company focuses on targeted therapies such as Ziihera, a bispecific HER2-directed antibody, addressing HER2-expressing solid tumors including biliary tract cancer under an accelerated U.S. approval.
Average Trading Volume: 766,516
Technical Sentiment Signal: Buy
Current Market Cap: $1.79B
See more insights into ZYME stock on TipRanks’ Stock Analysis page.